Journal of Korean medical science · 2026
Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеКлиническое исследование III фазыEquivalence TrialНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cho Young-Joo, Yoon Ho Joo, Lim Dae Hyun, Yoo Kwang Ha, Choi Sun-Hee, Rha Yeong-Ho
Аннотация
BACKGROUND: AG NPP709, formulated with extracts of ivy leaves and Coptis chinensis rhizomes, has antitussive and expectorant effects in preclinical rodent studies. We conducted a clinical trial to establish the efficacy and safety of the product compared with a widely prescribed ivy leaf extract product for the treatment of respiratory symptoms.
METHODS: In this randomized, double-blind, active-controlled, non-inferiority phase 3 trial, conducted in six hospitals in South Korea, symptomatic patients with acute upper respiratory infections (URIs) or chronic inflammatory bronchitis were randomized to receive either AG NPP709 or ivy leaf extract (control drug) for 5 days (n = 118 in each group). The primary efficacy endpoint was the clinical improvement rate, defined as the percentage of patients with symptoms evaluated as the top two scores on a five-point Likert scale at the end of the study (with a non-inferiority margin set at -15.0%).
RESULTS: The overall patient age ranged from 2 to 70 years, with a mean age of 24.9 years in the AG NPP709 group and 21.7 years in the control group. No statistical difference was observed in the clinical improvement rate, with a between-group difference of 4.3% (95% confidence interval: -8.9, 17.5). The symptom clearance rates (AG NPP709 vs. control) for cough and sputum were 43.0% vs. 40.0% (P = 0.655) and 34.6% vs. 25.5% (P = 0.142), respectively. The incidence of adverse events was similar in both groups (11.0% vs. 11.1%, P = 0.982), with most events being grade 1 or 2.
CONCLUSION: AG NPP709 was non-inferior to ivy leaf extract and had an acceptable safety profile. AG NPP709 could be an alternative treatment option for alleviating the symptoms associated with acute URI and chronic bronchitis.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01151202.
METHODS: In this randomized, double-blind, active-controlled, non-inferiority phase 3 trial, conducted in six hospitals in South Korea, symptomatic patients with acute upper respiratory infections (URIs) or chronic inflammatory bronchitis were randomized to receive either AG NPP709 or ivy leaf extract (control drug) for 5 days (n = 118 in each group). The primary efficacy endpoint was the clinical improvement rate, defined as the percentage of patients with symptoms evaluated as the top two scores on a five-point Likert scale at the end of the study (with a non-inferiority margin set at -15.0%).
RESULTS: The overall patient age ranged from 2 to 70 years, with a mean age of 24.9 years in the AG NPP709 group and 21.7 years in the control group. No statistical difference was observed in the clinical improvement rate, with a between-group difference of 4.3% (95% confidence interval: -8.9, 17.5). The symptom clearance rates (AG NPP709 vs. control) for cough and sputum were 43.0% vs. 40.0% (P = 0.655) and 34.6% vs. 25.5% (P = 0.142), respectively. The incidence of adverse events was similar in both groups (11.0% vs. 11.1%, P = 0.982), with most events being grade 1 or 2.
CONCLUSION: AG NPP709 was non-inferior to ivy leaf extract and had an acceptable safety profile. AG NPP709 could be an alternative treatment option for alleviating the symptoms associated with acute URI and chronic bronchitis.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01151202.